2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(1H-pyrazol-1-ylmethyl)benzoic acid | 1204595-09-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(1H-pyrazol-1-ylmethyl)benzoic acid
• CAS: 1204595-09-4
• 化学式: C₁₆H₁₆N₂O₄
• 分子量: 300.314
• InChiKey: KZYXFXQSDZFIRM-VOTSOKGWSA-N

反应信息

• 作为反应物：
  描述：

  2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(1H-pyrazol-1-ylmethyl)benzoic acid 在 5% Pd(II)/C(eggshell) 、 氢气 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 2.0h， 以73%的产率得到2-(3-ethoxy-3-oxopropyl)-5-(1H-pyrazol-1-ylmethyl)benzoic acid
  参考文献：
  名称：

  3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain

  摘要：

  A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl) propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE(2)-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.11.023
• 作为产物：
  描述：

  tert-butyl 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(1H-pyrazol-1-ylmethyl)benzoate 在 三氟乙酸 作用下， 以 苯甲醚 为溶剂， 反应 1.5h， 以76%的产率得到2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(1H-pyrazol-1-ylmethyl)benzoic acid
  参考文献：
  名称：

  3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain

  摘要：

  A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl) propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE(2)-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.11.023